Overview
Pro-Dex fiscal Q1 revenue grows 24% yr/yr, beating analyst expectations
Net income for fiscal Q1 more than doubles, aided by investment gains
Gross margin declines due to higher costs, including tariffs
Outlook
Company did not provide specific financial guidance in press release
Result Drivers
NEXT-GEN HANDPIECE - Revenue increase driven by resumption of next-gen handpiece shipments to largest customer
HIGHER COSTS - Gross margin decline attributed to higher costs, including tariffs, not fully passed to customers
INCREASED EXPENSES - Operating expenses rose due to higher personnel costs in HR, IT, and facilities
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q1 Revenue | Beat | $18.53 mln | $15.30 mln (1 Analyst) |
Q1 EPS | $1.40 | ||
Q1 Net Income | $4.68 mln | ||
Q1 Gross Profit | $5.36 mln | ||
Q1 Operating Expenses | $2.25 mln |
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Pro-Dex Inc is $56.00, about 45.2% above its October 29 closing price of $30.71
Press Release: ID:nACSn6Xjla
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)